食管癌放疗中MICA-NKG2D系统功能变化与疗效的临床研究

刘晓静; 刘平

doi:10.3969/j.issn.1672-2353.2009.21.005

食管癌放疗中MICA-NKG2D系统功能变化与疗效的临床研究

刘晓静,
刘平

南京医科大学第一临床医学院,江苏,南京,210029

详细信息

中图分类号: R735.1
计量
- 文章访问数: 134
- HTML全文浏览量: 32
- PDF下载量: 0
出版历程
- 发布日期: 2010-01-28

A clinical study on system function and efficacy of MICA-NKG2D in radiation treatment for Esophageal cancer

摘要

摘要: 目的探讨食管癌在放疗中MICA-NKG2D配受体功能变化,以及其变化与放疗疗效的关系.方法取食管鳞癌细胞株ECA109,用不同剂量照射后用流式细胞术检测MICA表达.采用ELISA法检测接受不同放疗剂量的食管癌患者血清中sMICA浓度,采用流式细胞术检测NK细胞NKG2D受体的表达,胞内染色法分析NK细胞杀伤靶细胞功能的变化,并在结束时及结束后4周,用WHO评价标准评价放疗疗效,研究NK细胞NKG2D受体的表达率提高与放疗疗效的关系.1年后评价生存率与NK细胞NKG2D受体的表达率提高的关系.结果食管鳞癌细胞株ECA109仅当32 Gy的照射量才能诱导MICA明显表达并促进NK细胞对其的杀伤效应.放疗中食管癌患者血清内sMICA含量无明显变化,40～60 Gy的放疗剂量时NKG2D阳性的NK细胞数增加,同时其NK细胞毒活性最强.放疗前后NKG2D阳性的NK细胞数增加越高的放疗后疗效评价越好.但1年后的评价未证实此结论 .结论放疗可以促使食管鳞癌细胞诱导MICA明显表达并促进NK细胞对其的杀伤效应.放疗中食管癌患者血清sMICA含量无明显变化,但放疗可使NKG2D阳性的NK细胞数增多,增加越明显的患者短期放疗疗效越好,但对远期1年生存率没有明显的影响.
- 放射治疗 /
- 食管癌 /
- MICA-NKG2D系统

HTML全文

参考文献(12)

Gleimer M, Parharm P. Stress management:MHC class l and class I-like molecules as reporters of cellular stress [J]. IMMUNITY, 2003(4):469.doi: 10.1016/S1074-7613(03)00272-3.

Cerwenka A, Lanier L L. NKG2D ligands:unconventional MHC class 1-like molecules exploited by viruses and cancer [J]. Tissue Antigens, 2003(5):335.doi: 10.1034/j.1399-0039.2003.00070.x.

Raulet D H. Rolesof theNKG2D immunoreceptor and its ligands [J]. Nature Reviews Immunology, 2003, (10):781.

Gasser S, Orsulic S, Brown E J. The DNA damage pathway regulates innate immune system ligands for the NKG2D receptor [J]. NATURE, 2005, (7054):1186.doi: 10.1038/nature03884.

González S, Lopez-Soto A, Suarez-Alvarez B. NKG2D ligands:key targets of the immune response [J]. Trends in Immunology, 2008(8):397.

Groh, V, J.Wu, C, Yee, T.Spies. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation [J]. Nature, 2002, (6908):734.doi: 10.1038/nature01112.

张彩, 冯进波, 王郡甫. 膜型分泌型MICA对NK细胞受体NKG2D的相反调节效应及其对NK细胞受体谱的影响 [J]. 中华微生物学和免疫学杂志, 2004(2):107.doi: 10.3760/j:issn:0254-5101.2004.02.008.

Gasser S, Orsulic S, Brown E J. The DNA damage pathway regulates innate immune system ligands for the NKG2D receptor [J]. NATURE, 2005, (7054):1186.doi: 10.1038/nature03884.

殷蔚伯, 谷铣之. 肿瘤放射治疗学 [M]. 北京:中国协和医科大学出版社, 2002.264.

Groh V, Wu J, Yee C. Tumor-derived soluble MIC ligands impair expression of NKG2D and T-cell activation [J]. Nature, 2002(9):734.doi: 10.1038/nature01112.

Jinushi M, Hodi F S, Dranoff G. Therapies-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity [J]. Proceedings of the National Academy of Sciences(USA), 2006(6):9190.doi: 10.1073/pnas.0603503103.

Groh V, Li Y Q, Cioca D. Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells [J]. Proceedings of the National Academy of Sciences(USA), 2005, (18):6461.doi: 10.1073/pnas.0501953102.

施引文献

资源附件(0)

计量

文章访问数: 134
HTML全文浏览量: 32
PDF下载量: 0
被引次数: 0

食管癌放疗中MICA-NKG2D系统功能变化与疗效的临床研究

计量

出版历程

A clinical study on system function and efficacy of MICA-NKG2D in radiation treatment for Esophageal cancer

计量

出版历程

目录